{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:57:50Z","timestamp":1773712670469,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Psychiatric and behavioural side effects are common, undesirable effects associated with antiseizure medication use. Temporal lobe epilepsy is the most common focal epilepsy in adults and it is frequently associated with drug resistance. Patients with intractable epilepsy are more likely to have psychiatric and behavioural side effects when taking antiseizure medications and seem to be at higher risk for psychiatric comorbidities. Perampanel is a novel anti-seizure medication approved for focal and generalised epilepsies as add-on therapy. This is a 12-week short-term observational prospective study on people with focal epilepsy consecutively recruited from an Italian tertiary epilepsy centre, aimed to compare incidence and severity of psychiatric and behavioural side effects associated with perampanel use in patients with temporal lobe epilepsy as compared to other focal epilepsies. All patients received add-on perampanel according to indication and clinical judgement. Incidence and severity of psychiatric and behavioural side effects were rated by Neuropsychiatric Inventory Questionnaire. All patients enrolled answered the questionnaire before starting perampanel and after 12 weeks of treatment. We found no significant difference in terms of incidence and severity of psychiatric and behavioural side effects associated with perampanel in patients with temporal lobe epilepsy as compared to other focal epilepsies. In line with the literature, the most common adverse effects were \u201cirritability\u201d for both groups and \u201caggression\u201d for patients with other focal epilepsies.<\/jats:p>","DOI":"10.3389\/fneur.2022.839985","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:52:01Z","timestamp":1646632321000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Psychiatric and Behavioural Side Effects Associated With Perampanel in Patients With Temporal Lobe Epilepsy. A Real-World Experience"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna","family":"Mamm\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Ferlazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Bova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Labate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta Lo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Aguglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","article-title":"Management of psychiatric and neurological comorbidities in epilepsy","volume":"12","year":"","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"1","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1111\/j.1528-1157.1999.tb00887.x","article-title":"Psychiatric syndromes related to antiepileptic drugs","volume":"40","author":"Schmitz","year":"1999","journal-title":"Epilepsia."},{"key":"B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav."},{"key":"B5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1053\/seiz.2000.0405","article-title":"Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables","volume":"4","author":"Trimble","year":"2000","journal-title":"Seizure."},{"key":"B6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jama.2012.220","article-title":"Early, Randomized Surgical Epilepsy Trial (ERSET) Study Group. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial","volume":"307","author":"Engel","year":"2012","journal-title":"JAMA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-244X-14-75","article-title":"The prevalence of psychosis in epilepsy; a systematic review and meta-analysis","volume":"13","author":"Clancy","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B8","unstructured":"Fycompa: EPAR - Product Information2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1080\/14656566.2017.1392509","article-title":"\u201cAMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives","volume":"18","author":"Di Bonaventura","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia."},{"key":"B16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.yebeh.2016.06.005","article-title":"Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours","volume":"61","author":"Maurousset","year":"2016","journal-title":"Epilepsy Behav."},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.775781","article-title":"\u201cTemporal lobe epilepsy and psychiatric comorbidity.\u201d","author":"Vinti","year":""},{"key":"B18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia."},{"key":"B19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory","volume":"12","author":"Kaufer","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"B21","unstructured":"Jamovi (Version 2.2.2)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia."},{"key":"B23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre","volume":"390","author":"Morano","year":"2018","journal-title":"J Neurol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10072-020-04636-7","article-title":"Perampanel as first add-on choice on the treatment of mesial temporal lobe epilepsy: an observational real-life study","volume":"442","author":"Labate","year":"2021","journal-title":"Neurol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"116903","DOI":"10.1016\/j.jns.2020.116903","article-title":"The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a \u201creal world\u201d context: focus on temporal lobe epilepsy","volume":"415","author":"Pascarella","year":"2020","journal-title":"J Neurol Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.839985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:52:03Z","timestamp":1646632323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.839985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":28,"alternative-id":["10.3389\/fneur.2022.839985"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.839985","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"article-number":"839985"}}